Summary
Methylprednisolone Acetate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. ClinicalTrials.gov lists 8 registered trials linking Methylprednisolone Acetate to Asthma: 1 is currently recruiting; 1 is active or not yet recruiting; 4 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT03900624). The largest enrolment is 159 participants (NCT07455396). Registration activity spans 2007 to 2026. The literature layer holds 2 publications for this pair: 2 clinical trial publications. Publication years run from 1969 to 1993. These are primary trial reports rather than syntheses, so results have not yet been pooled or graded independently.
The RepurpOS disease-intelligence file for Asthma ranks 642 candidate therapeutics from Open Targets, ChEMBL, DGIdb and PubMed; only a minority carry direct clinical evidence, and this page covers one of those. Spontaneous remission context recorded for the condition: 26% of childhood-onset asthma in clinical remission by adulthood; <20% adult-onset achieves sustained remission; 65% long-term remission in mild-moderate vs 16% in severe.
Evidence table
| Evidence tier | A · Strong |
|---|---|
| Evidence score | 46.0 (trials 22.0, literature 4.0, tier 15, approved bonus 5.0) |
| Registered trials | 8 total: 1 recruiting, 1 active / not yet recruiting, 4 completed, 2 other |
| Linked publications | 2 (2 clinical trial publications) |
| Agent type | Drug (Small molecule) |
| Development stage (any indication) | Approved |
| Mechanism / class | Not recorded |
| Data sources | Open Targets, ChEMBL |
How the evidence score is calculated
- Each registered trial scores by status (recruiting / active / enrolling 3, completed 2.5, not yet recruiting 2, unknown 1, terminated / withdrawn / suspended 0.5) plus a phase bonus (phase 3-4 +2, phase 2 +1, phase 1 +0.5). The trial component is capped at 30.
- Each literature item scores by design (Cochrane review 5, meta-analysis 4, systematic review 3, RCT 3, clinical trial publication 2, curated reference 1.5, other PubMed record 1). The literature component is capped at 30.
- The existing evidence tier adds 15 (A / Strong), 10 (B / Moderate), 5 (C / Preliminary) or 0 (D / Anecdotal).
- Agents approved for any indication (max clinical phase 4) add 5, because an approved agent has an established safety profile that lowers the barrier to repurposing trials.
- The score ranks what has been studied, not what works. It does not read effect sizes or directions of effect.
Registered clinical trials
| NCT ID | Title | Status | Phase | Enrolment |
|---|---|---|---|---|
| NCT03900624 | Ideal Steroids for Asthma Treatment in the PICU 2019 | completed | Phase 4 | 92 |
| NCT00627731 | Oral Glucocorticosteroid in the Treatment of Severe Asthma Exacerbation in Hospitalized Patients 2007 | completed | Phase 4 | 50 |
| NCT07455396 | Pediatric Asthma Trial of Corticosteroid Heterogeneity (PATCH): Trial of Dexamethasone Versus Methylprednisolone for Pediatric Critical Asthma 2026 | not yet recruiting | Phase 2 | 159 |
| NCT02872597 | Phase I, Placebo-Controlled, Blinded Pilot Study of Ipratropium in Children Admitted to the ICU With Status Asthmaticus 2016 | completed | Phase 1 | 30 |
| NCT04874610 | Steroid Metabolism in Obese and Non-Obese Pediatric Patients Hospitalized for Status Asthmaticus 2021 | completed | Not applicable | 15 |
| NCT00576069 | Mechanism(s)of Airflow Limitation in Moderate-severe Persistent Asthma 2007 | recruiting | Not applicable | 60 |
| NCT06171932 | Comparison Of Efficacy Of Hydrocortisone And Methyl Prednisolone In Acute Severe Asthma 2023 | status unknown | Not applicable | 60 |
| NCT00971893 | A Study To Assess The Safety And Effectiveness Of Medrol® In Acute Asthma In Indian Patients 2009 | withdrawn | Not applicable | — |
Published literature
- Clinical trial publication Intramuscular methylprednisolone acetate for the prevention of relapse in acute asthmaMcNamara RM, Rubin JM · Annals of emergency medicine · 1993 · PMID 8239103
- Clinical trial publication Comparison of preseasonal and coseasonal Allpyral with Depo-Medrone in summer hay-feverGanderton MA, Brostoff J, Frankland AW · British medical journal · 1969 · PMID 4883848
Mechanism and notes
No mechanism of action is recorded for this pair in the source databases.
OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Frequently asked questions
Is Methylprednisolone Acetate approved for Asthma?
Methylprednisolone Acetate has reached the approved stage (maximum clinical phase 4) for at least one indication, so its use in Asthma would be drug repurposing rather than first-in-human development. This does not mean it is approved for Asthma. Approval status for the specific indication should always be confirmed with the relevant regulator and prescribing information.
Is Methylprednisolone Acetate in clinical trials for Asthma?
ClinicalTrials.gov lists 8 registered trials linking Methylprednisolone Acetate to Asthma: 1 is currently recruiting; 1 is active or not yet recruiting; 4 have completed; 2 are terminated, withdrawn, suspended or of unknown status. The most advanced is Phase 4 (NCT03900624). The largest enrolment is 159 participants (NCT07455396). Registration activity spans 2007 to 2026.
What does the evidence show for Methylprednisolone Acetate in Asthma?
Methylprednisolone Acetate has 4 completed trials and 2 linked publications for Asthma. Completed trials may or may not have posted results; follow the NCT links to check. OSMF's existing evidence tier for this pair is A (Strong), derived from the strength of the disease association recorded in Open Targets and ChEMBL. The tier describes how well the drug-disease link is documented, not how well the drug works.
Cite this page
Data: ClinicalTrials.gov, PubMed, Open Targets, ChEMBL, DGIdb and the OSMF therapeutic agent database. Last updated 2026-07-05. Page built 2026-10-07.